New data from the Centers for Disease Control and Prevention shows Oregon is third worst in the nation for deaths from ...

As national data show Oregon's hepatitis C rates are among the worst in the nation, state officials are emphasizing a need for increased community-based screenings and prevention and treatment se ...

The FDA expanded the approval of the direct-acting antiviral (DAA) glecaprevir/pibrentasvir (Mavyret), making it the first ...

The country has recorded a surge of hepatitis cases, and the alarming situation has called for better clarity in ...

Mavyret marks the first and only direct-acting antiviral approved to treat both acute and chronic hepatitis C virus ...

The Hepatitis C Elimination Coalition commends Senators Bill Cassidy (R-LA) and Chris Van Hollen (D-MD) for their bipartisan ...

FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis ...

A Supreme Court decision that could overturn the Affordable Care Act’s coverage mandate for preventive health screenings ...

The FDA approved Mavyret for the treatment of patients 3 years and older with acute or chronic HCV infection without cirrhosis or with compensated cirrhosis.

COX'S BAZAR, Bangladesh -- As the U.S. and other countries slash their humanitarian aid budgets to focus on other priorities, Rohingya refugees are suffering.

AbbVie (NYSE:ABBV) recently secured FDA approval for the expanded use of MAVYRET, a treatment for hepatitis C, which now includes younger patients and those with acute HCV. This development is ...